文献リスト

1) 日本肝臓学会, 編. 科学的根拠に基づく肝癌診療ガイドライン2009年版. 東京: 金原出版; 2009

2) Sato T, Tateishi R, Yoshida H, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009; 3: 544-50

3) Noda I, Kitamoto M, Nakahara H, et al. Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2010; 45: 105-12

4) Tong MJ, Sun HE, Hsien C, et al. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010; 55: 826-35

5) Gannon CJ, Izzo F, Aloia TA, et al. Can hepatocellular cancer screening increase the proportion of long-term survivors？ Hepatogastroenterology. 2009; 56: 1152-6

6) Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010; 53: 291-7

7) Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009; 30: 37-47

8) Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011; 154: 85-93

9) Nakai M, Sato M, Ikoma A, et al. Triple-phase computed tomography during arterial portography with bolus tracking for hepatic tumors. Jpn J Radiol. 2010; 28: 149-56

10) Nakaura T, Awai K, Yanaga Y, et al. Detection of early enhancement of hypervascular hepatocellular carcinoma using single breath-hold 3D pixel shift dynamic subtraction MDCT. AJR Am J Roentgenol. 2008; 190: W13-8

11) Okumura E, Sanada S, Suzuki M, et al. Effectiveness of temporal and dynamic subtraction images of the liver for etection of small HCC on abdominal CT images: comparison of 3D nonlinear mage-warping and 3D global-matching techniques. Radiol Phys Technol. 2011 Jan 13. [Epub ahead of print]

12) Nishie A, Tajima T, Asayama Y, et al. Radiological assessment of hepatic vein invasion by hepatocellular carcinoma using combined computed tomography hepatic arteriography and computed tomography arterial portography. Jpn J Radiol. 2010; 28: 414-22

13) Sofue K, Tsurusaki M, Kawasaki R, et al. Evaluation of hypervascular hepatocellular carcinoma in cirrhotic liver: Comparison of different concentrations of contrast material with multi-detector row helical CT - A prospective randomized study. Eur J Radiol. 2010 Nov 8. [Epub ahead of print]

14) Akai H, Kiryu S, Takao H, et al. Efficacy of double-arterial phase gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced liver magnetic resonance imaging compared with double-arterial phase multi-detector row helical computed tomography. J Comput Assist Tomogr. 2009; 33: 887-92

15) Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: Comparison with triple phase 64 detector row helical CT. Eur J Radiol. 2010 Aug 21. [Epub ahead of print]

16) Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2009; 192: 1675-81

17) Kumano S, Uemura M, Haraikawa T, et al. Efficacy of double arterial phase dynamic magnetic resonance imaging with the sensitivity encoding technique versus dynamic multidetector-row helical computed tomography for detecting hypervascular hepatocellular carcinoma. Jpn J Radiol. 2009; 27: 229-36

18) Pitton MB, Kloeckner R, Herber S, et al. MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009; 15: 6044-51

19) Marin D, Di Martino M, Guerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology. 2009; 251: 85-95

20) Kim YK, Kim CS, Han YM, et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr. 2009; 33: 844-50

21) Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010; 45: 133-41

22) Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010; 256: 806-16

23) Haradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: Comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging. 2011; 34: 69-78

24) Yoon JH, Lee EJ, Cha SS, et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol. 2010; 21: 348-56

25) Sutcliffe RP, Lewis D, Kane PA, et al. Manganese-enhanced MRI predicts the histological grade of hepatocellular carcinoma in potential surgical candidates. Clin Radiol. 2011; 66: 237-43

26) Lee MW, Kim YJ, Park HS, et al. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol. 2010; 194: W396-400

27) Xu PJ, Yan FH, Wang JH, et al. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging. 2009; 29: 341-9

28) Vandecaveye V, De Keyzer F, Verslype C, et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol. 2009; 19: 2456-66

29) Nishie A, Tajima T, Ishigami K, et al. Detection of hepatocellular carcinoma (HCC) using super paramagnetic iron oxide (SPIO)-enhanced MRI: Added value of diffusion-weighted imaging (DWI). J Magn Reson Imaging. 2010; 31: 373-82

30) Piana G, Trinquart L, Meskine N, et al. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol. 2011; 55: 126-32

31) Yu JS, Chung JJ, Kim JH, et al. Detection of small intrahepatic metastases of hepatocellular carcinomas using diffusion-weighted imaging: comparison with conventional dynamic MRI. Magn Reson Imaging. 2011 May 24. [Epub ahead of print]

32) Muhi A, Ichikawa T, Motosugi U, et al. High-b-value diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma. J Magn Reson Imaging. 2009; 30: 1005-11

33) Catalano OA, Choy G, Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology. 2010; 254: 154-62

34) Xu PJ, Yan FH, Wang JH, et al. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr. 2010; 34: 506-12

35) Park HS, Lee JM, Kim SH, et al. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla. J Magn Reson Imaging. 2009; 29: 328-35

36) Nasu K, Kuroki Y, Tsukamoto T, et al. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol. 2009; 193: 438-44

37) Yoo HJ, Lee JM, Lee JY, et al. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver. Invest Radiol. 2009; 44: 800-7

38) Matsushima M, Naganawa S, Ikeda M, et al. Diagnostic value of SPIO-mediated breath-hold, black-blood, fluid-attenuated, inversion recovery (BH-BB-FLAIR) imaging in patients with hepatocellular carcinomas. Magn Reson Med Sci. 2010; 9: 49-58

39) Lee JY, Kim SH, Jeon YH, et al. Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr. 2010; 34: 127-34

40) Macarini L, Milillo P, Cascavilla A, et al. MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers. Radiol Med. 2009; 114: 1267-82

41) Saito K, Sugimoto K, Nishio R, et al. Perfusion study of liver lesions with superparamagnetic iron oxide: distinguishing hepatocellular carcinoma from focal nodular hyperplasia. Clin Imaging. 2009; 33: 447-53

42) Okada M, Imai Y, Kim T, et al. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2010; 32: 903-13

43) Ishigami K, Tajima T, Fujita N, et al. Hepatocellular carcinoma with marginal superparamagnetic iron oxide uptake on T2＊-weighted magnetic resonance imaging: Histopathologic correlation. Eur J Radiol. 2011 Jan 31. [Epub ahead of print]

44) Koda M, Tokunaga S, Fujise Y, et al. Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition. Eur J Radiol. 2011 Mar 24. [Epub ahead of print]

45) Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol. 2009; 193: 1053-60

46) Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology. 2010; 256: 151-8

47) Haradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: Comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging. 2011 May 19. doi: 10. 1002/jmri. 22588. [Epub ahead of print]

48) Kim JE, Kim SH, Lee SJ, et al. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: Characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol. 2011; 196: W758-65

49) Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (＜ or ＝2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol. 2010; 45: 96-103

50) Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010; 20: 2405-13

51) Kobayashi S, Matsui O, Gabata T, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma. J Comput Assist Tomogr. 2011; 35: 181-6

52) Lee S, Kim SH, Park CK, et al. Comparison between areas with Gd-EOB-DTPA uptake and without in hepatocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation. J Magn Reson Imaging. 2010; 32: 719-25

53) Asayama Y, Tajima T, Nishie A, et al. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: Radiologic-pathologic correlation with special reference to bile production. Eur J Radiol. 2010 Nov 23. [Epub ahead of print]

54) Lee SA, Lee CH, Jung WY, et al. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience. Magn Reson Imaging. 2011; 29: 83-90

55) Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009; 44: 793-8

56) Choi JS, Kim MJ, Choi JY, et al. Diffusion-weighted MR imaging of liver on 3. 0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol. 2010; 20: 1052-60

57) Saito K, Araki Y, Park J, et al. Effect of Gd-EOB-DTPA on T2-weighted and diffusion-weighted images for the diagnosis of hepatocellular carcinoma. J Magn Reson Imaging. 2010; 32: 229-34

58) Motosugi U, Ichikawa T, Sou H, et al. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). J Magn Reson Imaging. 2009; 30: 849-54

59) Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol. 2011; 46: 141-5

60) Tajima T, Takao H, Akai H, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010; 34: 362-6

61) Strobel D, Seitz K, Blank W, et al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1, 349 liver lesions in contrast-enhanced ultrasound (CEUS). Ultraschall Med. 2009; 30: 376-82

62) Massironi S, Della Corte C, Sangiovanni A, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010; 59: 638-44

63) Korenaga K, Korenaga M, Furukawa M, et al. Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images. J Gastroenterol. 2009; 44: 733-41

64) von Herbay A, Vogt C, Westendorff J, et al. Correlation between SonoVue enhancement in CEUS, HCC differentiation and HCC diameter: analysis of 130 patients with hepatocellular carcinoma (HCC). Ultraschall Med. 2009; 30: 544-50

65) Hatanaka K, Chung H, Kudo M, et al. Usefulness of the post-vascular phase of contrast-enhanced ultrasonography with sonazoid in the evaluation of gross types of hepatocellular carcinoma. Oncology. 2010; 78 Suppl 1: 53-9

66) Takahashi M, Maruyama H, Ishibashi H, et al. Contrast-enhanced ultrasound with perflubutane microbubble agent: evaluation of differentiation of hepatocellular carcinoma. AJR Am J Roentgenol. 2011; 196: W123-31

67) Seitz K, Bernatik T, Strobel D, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients. Ultraschall Med. 2010; 31: 492-9

68) Kawada N, Ohkawa K, Tanaka S, et al. Improved diagnosis of well-differentiated hepatocellular carcinoma with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid-enhanced magnetic resonance imaging and Sonazoid contrast-enhanced ultrasonography. Hepatol Res. 2010; 40: 930-6

69) Mandai M, Koda M, Matono T, et al. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol. 2011; 84: 499-507

70) Pei XQ, Liu LZ, Zheng W, et al. Contrast-enhanced ultrasonography of hepatocellular carcinoma: Correlation between quantitative parameters and arteries in neoangiogenesis or sinusoidal capillarization. Eur J Radiol. 2011 Feb 22. [Epub ahead of print]

71) Moschouris H, Malagari K, Papadaki MG, et al. Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisation using drug-eluting beads: a pilot study focused on sustained tumor necrosis. Cardiovasc Intervent Radiol. 2010; 33: 1022-7

72) Lassau N, Chebil M, Chami L, et al. Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target Oncol. 2010; 5: 53-8

73) Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology. 2011; 258: 291-300

74) Lassau N, Chami L, Chebil M, et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med. 2011; 11: 18-24

75) Zorger N, Jung EM, Schreyer AG, et al. Ultrasound-arterioportography (US-AP): A new technical approach to perform detection of liver lesions. Clin Hemorheol Microcirc. 2010; 46: 117-26

76) Schacherer D, Girlich C, Zorger N, et al. Sono-hepatic-arteriography (Sono-HA) in the assessment of hepatocellular carcinoma in patients undergoing transcatheter arterial chemo-embolization (TACE). Ultraschall Med. 2010; 31: 270-5

77) Jung EM, Schreyer AG, Schacherer D, et al. New real-time image fusion technique for characterization of tumor vascularisation and tumor perfusion of liver tumors with contrast-enhanced ultrasound, spiral CT or MRI: first results. Clin Hemorheol Microcirc. 2009; 43: 57-69

78) Fukuda H, Ito R, Ohto M, et al. US-CT 3D dual imaging by mutual display of the same sections for depicting minor changes in hepatocellular carcinoma. Eur J Radiol. 2011 Jun 13. [Epub ahead of print]

79) Jung EM, Schreyer AG, Schacherer D, et al. New real-time image fusion technique for characterization of tumor vascularisation and tumor perfusion of liver tumors with contrast-enhanced ultrasound, spiral CT or MRI: first results. Clin Hemorheol Microcirc. 2009; 43: 57-69

80) Kisaka Y, Hirooka M, Koizumi Y, et al. Contrast-enhanced sonography with abdominal virtual sonography in monitoring radiofrequency ablation of hepatocellular carcinoma. J Clin Ultrasound. 2010; 38: 138-44

81) Ross CJ, Rennert J, Schacherer D, et al. Image fusion with volume navigation of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) for post-interventional follow-up after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas (HCC): Preliminary results. Clin Hemorheol Microcirc. 2010; 46: 101-15

82) Kawaoka T, Aikata H, Takaki S, et al. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res. 2009; 39: 134-42

83) Yen RF, Chen CY, Cheng MF, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010; 31: 637-45

84) Ho CL, Chen S, Cheng TK, et al. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology. 2011; 258: 515-23

85) Wolfort RM, Papillion PW, Turnage RH, et al. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg. 2010; 95: 67-75

86) Sun L, Guan YS, Pan WM, et al. Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT. World J Hepatol. 2009; 1: 90-7

87) Yim HJ, Yeon JE, Byun KS, et al. Laparoscopic resection of HCC implanted in the peritoneal cavity: a case detected by PET after hepatic resection. Hepatogastroenterology. 2008; 55: 1549-52

88) Han AR, Gwak GY, Choi MS, et al. The clinical value of 18F-FDG PET/CT for investigating unexplained serum AFP elevation following interventional therapy for hepatocellular carcinoma. Hepatogastroenterology. 2009; 56: 1111-6

89) Kim HO, Kim JS, Shin YM, et al. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. J Nucl Med. 2010; 51: 1849-56

90) Talbot JN, Fartoux L, Balogova S, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010; 51: 1699-706

91) Dierckx R, Maes A, Peeters M, et al. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging. 2009; 53: 336-42

92) Higashi T, Hatano E, Ikai I, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2010; 37: 468-82

93) Shin DY, Han SW, Oh DY, et al. Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort. Cancer Chemother Pharmacol. 2010 Sep 25. [Epub ahead of print]

94) Kim BK, Kang WJ, Kim JK, et al. (18) F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011 Apr 5. doi: 10. 1002/cncr. 26099. [Epub ahead of print]

95) Kim JW, Seong J, Yun M, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2011 May 11. [Epub ahead of print]

96) Liu Y, Chen Z, Liu C, et al. Gadolinium-loaded polymeric nanoparticles modified with anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials. 2011; 32: 5167-76

97) Rennert J, Jung EM, Schreyer AG, et al. MR-arterioportography: a new technical approach for detection of liver lesions. World J Gastroenterol. 2011; 17: 1739-45

98) Ishizawa T, Fukushima N, Shibahara J, et al. Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer. 2009; 115: 2491-504

99) Kim YS, Lee WJ, Rhim H, et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (＞ 2 and ＜ 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010; 195: 758-65

100) Hwang J, Kim SH, Kim YS, et al. Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy. J Magn Reson Imaging. 2010; 32: 629-38

101) Tajima T, Nishie A, Asayama Y, et al. Safety margins of hepatocellular carcinoma demonstrated by 3-dimensional fused images of computed tomographic hepatic arteriography/unenhanced computed tomography: prognostic significance in patients who underwent transcatheter arterial chemoembolization. J Comput Assist Tomogr. 2010; 34: 712-9

102) Kloeckner R, Otto G, Biesterfeld S, et al. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010; 33: 532-40

103) Kalb B, Chamsuddin A, Nazzal L, et al. Chemoembolization follow-up of hepatocellular carcinoma with MR imaging: usefulness of evaluating enhancement features on one-month posttherapy MR imaging for predicting residual disease. J Vasc Interv Radiol. 2010; 21: 1396-404

104) Yuan Z, Ye XD, Dong S, et al. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol. 2010; 75: e9-14

105) Chung JC, Naik NK, Lewandowski RJ, et al. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol. 2010; 16: 3161-7

106) Kubota K, Yamanishi T, Itoh S, et al. Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma. Oncol Rep. 2010; 24: 727-32

107) Mannelli L, Kim S, Hajdu CH, et al. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol. 2009; 193: 1044-52

108) Wang D, Gaba RC, Jin B, et al. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol. 2011; 18: 828-36

109) Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer. 2009; 9: 208

110) Hsu CY, Shen YC, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol. 2011 Feb 19. [Epub ahead of print]

111) Schraml C, Schwenzer NF, Martirosian P, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol. 2009; 193: W301-7

112) Lewin M, Fartoux L, Vignaud A, et al. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol. 2011; 21: 281-90

113) Jiang T, Kambadakone A, Kulkarni NM, et al. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol. 2011 May 13. [Epub ahead of print]

114) Maksimovic O, Schraml C, Hartmann JT, et al. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol. 2010; 194: 5-14

115) Spira D, Fenchel M, Lauer UM, et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol. 2011; 18: 89-96

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp